RxDoctor Payments Data

Saema Mirza, MD

Cardiovascular Disease · Birmingham, ALNPI 1356330054

Payments from drug & device makers

$617in general payments, 2019–2025

Across 24 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$212
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$142
  • Novo Nordisk$98
  • Johnson & Johnson$69
  • Abbott$40
  • AstraZeneca$27
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$617 in reported general payments places this provider in the 20th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$155,818
Medicare patients
693
Services billed
2,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban717$695,257
EntrestoSacubitril/Valsartan228$248,032
XareltoRivaroxaban108$95,242
Repatha SureclickEvolocumab64$55,345
JardianceEmpagliflozin35$42,423
Rosuvastatin Calcium670$15,351
Metoprolol Succinate761$14,502
FarxigaDapagliflozin Propanediol18$13,199
Ranolazine ErRanolazine84$12,469
Olmesartan Medoxomil293$8,545
Carvedilol736$7,146
Atorvastatin Calcium442$6,926
Flecainide Acetate66$6,188
Ezetimibe181$5,549
Amlodipine Besylate744$5,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$15$248,032228 claims
Johnson & JohnsonXarelto$69$95,242108 claims
AstraZenecaFarxiga$27$13,19918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →